CYT-338, an investigational myeloma therapy designed to simultaneously bind to cancer cells and activate immune cells called natural killer cells, has shown promising anti-cancer activity in preclinical studies. A team led by scientists at Cytovia Therapeutics, the company developing CYT-338, will present the findings in a poster this month at the European Hematology Association’s 2022 Hybrid Congress, taking place both online and in Vienna, Austria, June 9–12. The poster is titled, “Novel Multifunctional Tetravalent CD38…
June 07, 2022June 7, 2022